

# Some pharmacological and biochemical interactions of the enantiomers of adenylyl 5'-( $\beta$ , $\gamma$ -methylene)-diphosphonate with the guinea-pig urinary bladder

N.J. Cusack & S.M.O. Hourani

Department of Pharmacology, University of London King's College, Strand, London WC2R 2LS

1 Adenosine 5'-triphosphate (ATP) and adenylyl 5'-( $\beta$ ,  $\gamma$ -methylene)-diphosphonate (AMP-PCP) both contracted the guinea-pig urinary bladder, but the response to AMP-PCP was much greater. We synthesized the enantiomer of AMP-PCP, L-adenylyl 5'-( $\beta$ ,  $\gamma$ -methylene)-diphosphonate (L-AMP-PCP), and tested it on the guinea-pig bladder.

2 L-AMP-PCP contracted the guinea-pig bladder, and was more potent than AMP-PCP and much more potent than ATP. The potential breakdown product of L-AMP-PCP, L-adenosine, unlike adenosine (the breakdown product of AMP-PCP), did not inhibit contractions of the guinea-pig bladder.

3 ATP and its enantiomer L-adenosine 5'-triphosphate (L-ATP) were rapidly degraded by the muscle, and AMP-PCP was also degraded, but more slowly. L-AMP-PCP, however, was completely resistant to degradation.

4 L-AMP-PCP would appear to be a useful ATP analogue, as it is potent and resistant to degradation, and its potential breakdown product, L-adenosine, is inactive.

## Introduction

The pharmacological actions of adenosine 5'-triphosphate (ATP) on many smooth muscle systems may be complicated by the breakdown of ATP to adenosine, which is less active than, or in some cases has the opposite action to ATP (Burnstock & Brown, 1981; Maguire & Satchell, 1981). This complication has been partly overcome by the use of analogues which are thought to be more resistant to enzymatic degradation by the tissue, such as adenylyl 5'-( $\beta$ ,  $\gamma$ -methylene)-diphosphonate (AMP-PCP), in which one of the ester oxygen linkages between the phosphate groups has been replaced by a methylene linkage (Maguire & Satchell, 1979).

In the guinea-pig bladder ATP causes contraction, but is not a very potent agonist (Ambache & Zar, 1970; Ambache *et al.*, 1977), and this has been attributed to its rapid degradation to adenosine, which inhibits contraction of the guinea-pig bladder (Burnstock *et al.*, 1972; Lukacsko & Krell, 1981). ATP and adenosine act on separate purinoceptors, which have been called  $P_2$  and  $P_1$  respectively (Burnstock, 1978).  $P_1$  receptors in other tissues are stereospecific, the unnatural enantiomer of adenosine, L-adenosine, being completely inactive (Cusack *et al.*, 1979; Cusack & Planker, 1979; Brown *et al.*, 1982).

$P_2$ -receptors, on the other hand, display only limited stereoselectivity (Cusack & Planker, 1979), and in the guinea-pig bladder the unnatural enantiomer of ATP, L-adenosine 5'-triphosphate (L-ATP), is almost equipotent with ATP (Burnstock *et al.*, 1983).

The enantiomer of AMP-PCP, L-adenylyl 5'-( $\beta$ ,  $\gamma$ -methylene)-diphosphonate (L-AMP-PCP), might prove to be a very useful  $P_2$ -receptor agonist in the bladder, as it seems likely to combine high potency with resistance to degradation, and its potential breakdown product, L-adenosine, is probably inactive. We therefore synthesized L-AMP-PCP, and investigated the pharmacological effects of AMP-PCP and L-AMP-PCP on the guinea-pig isolated urinary bladder, and compared the degradation of these two analogues by the bladder with the degradation of ATP and L-ATP.

## Methods

### Pharmacological studies

Male albino guinea-pigs (300 to 500 g) were stunned by a blow to the head and exsanguinated. Mucosa-

free detrusor strips ( $10 \times 2$  mm) were prepared from the urinary bladder and attached by thread to a rigid support. The preparations were superfused with modified Krebs solution of the following ionic composition (mM): NaCl 120, KCl 5.9,  $MgCl_2$  1.2,  $NaHCO_3$  15.4,  $NaH_2PO_4$  1.2,  $CaCl_2$  2.5 and glucose 11.5, containing atropine ( $1 \mu M$ ) and guanethidine ( $3.4 \mu M$ ). The Krebs solution was gassed with 95%  $O_2$  and 5%  $CO_2$  and warmed to  $35^\circ C$ , and flow rate was  $1 \text{ ml min}^{-1}$ . The detrusor strips were initially mounted under 1 g tension, and mechanical activity was recorded isometrically with a Grass FT10C transducer and displayed on a Grass 79C polygraph. The preparations were equilibrated for 60 min before addition of drugs or nerve stimulation.

Non-adrenergic, non-cholinergic nerves were stimulated electrically via platinum ring electrodes by means of a Grass SD9 stimulator at a voltage of 40 V with a pulse duration of 0.3 ms and a range of frequencies from 0.2 to 50 Hz, applied in a decreasing order throughout the experiment. Drugs were added to the Krebs solution and passed through the superfusion apparatus and drug application or nerve stimulation was maintained until the tension of the detrusor strips had reached a maximum and declined. Concentration-response curves or frequency-response curves were obtained non-cumulatively, with at least 10 min washout between drug applications or nerve stimulations, and up to 30 min after high concentrations of agonists. All contractions are expressed as a percentage of the mean of three consecutive contractions induced by nerve stimulation at 50 Hz at the beginning of each experiment.

To investigate the effect of adenosine or L-adenosine on the responses of the detrusor strips to nerve stimulation, the preparations were superfused with adenosine or with L-adenosine at a concentration of  $100 \mu M$  for 90 s before stimulating non-adrenergic, non-cholinergic nerves. For each frequency of stimulation, a control response was obtained, followed after washout by a response in the presence of adenosine and then, after another washout, by a response in the presence of L-adenosine.

### Degradation studies


Guinea-pig detrusor strips prepared as described above were equilibrated for at least 60 min at  $35^\circ C$  in Krebs solution containing atropine and guanethidine, the solution being replaced every 10 min. Each strip was then placed in a small tube with Krebs solution ( $600 \mu l$ ) at  $35^\circ C$ , containing ATP, L-ATP, AMP-PCP or L-AMP-PCP ( $100 \mu M$ ). At various time intervals, aliquots ( $70 \mu l$ ) were withdrawn and frozen for later analysis by high performance liquid chromatography (h.p.l.c.). As a control for non-enzymatic breakdown, ATP ( $100 \mu M$ ) was

incubated in the Krebs solution for 60 min at  $35^\circ C$  without a muscle strip. As a control for the possible release of nucleotides or enzymes, one muscle strip was incubated at  $35^\circ C$  for 60 min in Krebs solution alone, and an aliquot ( $70 \mu l$ ) was then taken for analysis by h.p.l.c. The muscle strip was removed and ATP was added at a final concentration of  $100 \mu M$ , and the incubation was continued for a further 60 min, after which another aliquot ( $70 \mu l$ ) was taken for analysis.


Degradation of nucleotides was followed by ion-exchange h.p.l.c. as described by Cusack *et al.* (1983), using a Whatman Partisil 10-SAX column eluted with a linear gradient (0.01 to  $1 M$   $KH_2PO_4$ ,  $2 \text{ ml min}^{-1}$ , over 15 min). Samples ( $60 \mu l$ ) of the aliquots were directly applied to the column after a brief centrifugation at  $12000 g$  in an Eppendorf centrifuge. The separated nucleosides and nucleotides were detected by ultraviolet absorption at 259 nm, and their concentrations were estimated by measuring the areas under the corresponding peaks displayed on a chart recorder, and expressed as a percentage of the area of the peak for the starting material. These areas were linearly related to concentration up to  $100 \mu M$ , and the lower limit of detection was  $2 \mu M$ .

### Drugs

Adenosine, ATP, AMP-PCP and atropine sulphate were obtained from Sigma, London. Guanethidine monosulphate was obtained from Ciba Laboratories, Horsham. L-Adenosine (9- $\beta$ -L-ribofuranosyladenine) was synthesized by the method of Holý & Sorm (1969). L-ATP was synthesized by phosphorylation of L-adenosine by the method of Holý & Sorm (1971), and L-AMP-PCP was synthesized from L-adenosine as described by Cusack *et al.* (1983).



**Figure 1** Contraction of the guinea-pig bladder by ATP (■), AMP-PCP (▲) or L-AMP-PCP (●). Each point is the mean of at least 10 determinations using bladder strips from at least 5 different guinea-pigs. Vertical bars show the standard errors of the mean.




**Figure 2** Contraction of the guinea-pig bladder by non-cholinergic, non-adrenergic nerve stimulation in the absence (▲) or presence of adenosine (100  $\mu$ M) (□) or L-adenosine (100  $\mu$ M) (○). Each point is the mean of at least 10 determinations using bladder strips from at least 5 different guinea-pigs. Vertical bars show the standard errors of the mean.

## Results


### Pharmacological studies

AMP-PCP and L-AMP-PCP, like ATP, both caused contraction of the guinea-pig bladder, but were more potent than ATP and achieved a greater maximal contraction (Figure 1). L-AMP-PCP was more potent than AMP-PCP, and achieved a slightly greater maximal contraction.

Adenosine (100  $\mu$ M) inhibited the nerve-mediated contraction of the guinea-pig bladder, but L-adenosine (100  $\mu$ M) was completely inactive (Figure 2). The inhibition by adenosine, although small, was consistent in that adenosine always reduced the re-



**Figure 3** Degradation of ATP (100  $\mu$ M) (●) to ADP (Δ), AMP (▽) and adenosine (□) by the guinea-pig bladder. Concentrations were estimated from the areas under the corresponding peaks obtained after h.p.l.c., and expressed as a percentage of the area of the ATP peak before incubation.



**Figure 4** Degradation of L-ATP (100  $\mu$ M) (●) to L-ADP (Δ), L-AMP (▽) and L-adenosine (□). Concentrations were estimated from the areas under the corresponding peaks obtained after h.p.l.c., and expressed as a percentage of the area of the L-ATP peak before incubation.


sponse to each frequency of nerve stimulation in every tissue preparation, and, unlike L-adenosine, inhibited the spontaneous contractions of the muscle.

### Degradation studies

Degradation of ATP (100  $\mu$ M) was rapid, being detectable after 1 min and almost complete after 20 min. The main breakdown product was adenosine, although the intermediates, adenosine 5'-diphosphate (ADP) and adenosine 5'-monophosphate (AMP) were also detected (Figure 3). L-ATP (100  $\mu$ M) was degraded less rapidly than ATP, and although breakdown was detected after 1 min, after 20 min about 30% of the L-ATP remained. The main breakdown products were L-adenosine 5'-diphosphate (L-ADP) and L-adenosine 5'-monophosphate (L-AMP), although L-adenosine was detectable after 20 min (Figure 4).

AMP-PCP (100  $\mu$ M) was degraded much more slowly than ATP, and even after 60 min, approximately 40% remained. The main degradation product was adenosine, and no AMP was detected (Figure 5). L-AMP-PCP (100  $\mu$ M) was completely resistant to degradation, and no breakdown products could be detected even after 60 min (Figure 5).

In the case of ATP and of AMP-PCP, somewhat less adenosine was detected after the longer incubation times than would have been expected from the corresponding breakdown of the starting materials (Figures 3 and 5), and this is presumably due to some uptake of adenosine by the muscle (Maguire & Satchell, 1981).



**Figure 5** Degradation of AMP-PCP (100  $\mu$ M) (●) to adenosine (□), and resistance to degradation of L-AMP-PCP (100  $\mu$ M) (○). Concentrations were estimated from the areas under the corresponding peaks obtained after h.p.l.c., and expressed as a percentage of the area under the peak of the starting material.

ATP (100  $\mu$ M) incubated with Krebs solution alone for 60 min was completely unchanged, and there was no detectable release of nucleotides or nucleosides by the muscle after 60 min incubation. ATP (100  $\mu$ M) added to Krebs solution which had been incubated with muscle for 60 min was unchanged after a further 60 min incubation in the absence of the muscle, indicating that no enzymes which could degrade ATP had been released.

## Discussion

These results show that L-AMP-PCP contracted the guinea-pig bladder, and was more potent than AMP-PCP and much more potent than ATP. The lack of stereoselectivity of this  $P_2$ -receptor is in agreement with the results of Burnstock *et al.* (1983), who found that ATP and L-ATP were almost equipotent at inducing contractions of the guinea-pig bladder.

Considerable indirect evidence has accumulated to suggest that ATP, and to a lesser extent AMP-PCP,

are broken down to adenosine by smooth muscle preparations, fast enough to affect pharmacological responses (Maguire & Satchell, 1981). To our knowledge, however, no direct measurement of this breakdown has been reported, although there is a detailed study of the breakdown of ATP and several of its analogues, including L-ATP, AMP-PCP and L-AMP-PCP, by pig aortic endothelial cells in culture (Cusack *et al.*, 1983).

Our results show that detectable breakdown of ATP and of L-ATP occurred within 1 min, and that AMP-PCP was also degraded, but more slowly. The greater potency of AMP-PCP than of ATP could therefore indeed be due to its comparative resistance to degradation, as previously suggested (Brown *et al.*, 1979; Lukacsco & Krell, 1982). Degradation of L-AMP-PCP, on the other hand, was not detected even after 60 min incubation, and this greater resistance to degradation could explain its higher potency relative to AMP-PCP. The inactivity of L-adenosine as an inhibitor of contraction shows that the  $P_1$ -receptor of the guinea-pig bladder, like the  $P_1$ -receptor on other tissues (Cusack *et al.*, 1979; Cusack & Planker, 1979; Brown *et al.*, 1982), was stereospecific. Even if there was some local degradation of L-AMP-PCP, undetectable in our experiments, the breakdown products would therefore be inactive at this adenosine receptor.

L-AMP-PCP, like AMP-PCP (Lukascko & Krell, 1982), causes desensitization of the guinea-pig bladder to ATP (Hourani, 1984), which is evidence that these analogues act at the  $P_2$ -receptor, although in the absence of a specific, competitive ATP antagonist final proof is lacking. However, the high potency of L-AMP-PCP on the guinea-pig bladder, combined with its resistance to degradation and the lack of activity of any breakdown products on the inhibitory  $P_1$ -receptor, would appear to make this compound an attractive new ATP analogue for the study of  $P_2$ -receptors in this tissue.

We thank the Medical Research Council for financial support (G8111856SA and G8217312SA), the British Heart Foundation (81/32) and the Fritz Thyssen Stiftung for equipment grants, and Professor G.V.R. Born, F.R.C.P., F.R.S., for encouragement.

## References

- AMBACHE, N. & ZAR, M.A. (1970). Non-cholinergic transmission by post-ganglionic motor neurones in the mammalian bladder. *J. Physiol.*, **210**, 761–783.
- AMBACHE, N., KILLICK, S.W. & WOODLEY, J.P. (1977). Evidence against purinergic motor transmission in the guinea-pig urinary bladder. *Br. J. Pharmac.*, **61**, 464P.
- BROWN, C., BURNSTOCK, G. & COCKS, T. (1979). Effects of adenosine 5'-triphosphate (ATP) and  $\beta$ , $\gamma$ -methylene ATP on the rat urinary bladder. *Br. J. Pharmac.*, **65**, 97–102.
- BROWN, C., BURNSTOCK, G., CUSACK, N.J., MEGHJI, P. & MOODY, C.J. (1982). Evidence for stereospecificity of the  $P_1$ -purinoceptor. *Br. J. Pharmac.*, **75**, 101–107.
- BURNSTOCK, G. (1978). A basis for distinguishing two

- types of purinergic receptor. In *Cell Membrane Receptors for Drugs and Hormones: a Multidisciplinary Approach*. ed. Bolis, L. & Straub, R.W. pp. 107–118. New York: Raven Press.
- BURNSTOCK, G. & BROWN, C.M. (1981). An introduction to purinergic receptors. In *Purinergic Receptors. Receptors and Recognition, Series B*, Vol. 12, ed. Burnstock, G. pp. 1–45. London: Chapman & Hall.
- BURNSTOCK, G., CUSACK, N.J., HILLS, J.M., MacKENZIE, I., & MEGHJI, P. (1983). Studies on the stereoselectivity of the P<sub>2</sub>-purinoceptor. *Br. J. Pharmac.*, **79**, 907–913.
- BURNSTOCK, G., DUMSDAY, B. & SMYTHE, A. (1972). Atropine resistant excitation of the urinary bladder: the possibility of transmission via nerves releasing a purine nucleotide. *Br. J. Pharmac.*, **44**, 451–461.
- CUSACK, N.J., HICKMAN, M.E. & BORN, G.V.R. (1979). Effects of D- and L- enantiomers of adenosine, AMP and ADP and their 2-chloro- and 2-azido- analogues on human platelets. *Proc. R. Soc. B*, **206**, 139–144.
- CUSACK, N.J., PEARSON, J.D. & GORDON, J.L. (1983). Stereoselectivity of ectonucleotidases on vascular endothelial cells. *Biochem. J.*, **214**, 975–981.
- CUSACK, N.J. & PLANKER, M. (1979). Relaxation of isolated taenia coli of guinea-pig by enantiomers of 2-azido analogues of adenosine and adenine nucleotides. *Br. J. Pharmac.*, **67**, 153–158.
- HOLÝ, A. & SORM, F. (1969). Oligonucleotidic compounds. XXXIV. Preparation of some  $\beta$ -L-ribonucleosides, their 2'(3')-phosphates and 2',3'-cyclic phosphates. *Colln. Czech. chem. Commun. Engl. Edn.*, **34**, 3383–3401.
- HOLÝ, A. & SORM, F. (1971). Nucleic acid components and their analogues. CXL. Preparation of 5'-L-ribonucleotides, some of their derivatives, and 2'(3') $\rightarrow$ 5'-homooligo- L-ribonucleotides: coding properties of L-ribonucleoside-containing oligonucleotides. *Colln. Czech. chem. Commun. Engl. Edn.*, **36**, 3283–3299.
- HOURLANI, S.M.O. (1984). Desensitization of the guinea-pig urinary bladder by the enantiomers of adenylyl 5'-( $\beta$ , $\gamma$ -methylene)-diphosphonate and by substance P. *Br. J. Pharmac.*, (Ms. 493-companion paper-details at make-up).
- LUKACSKO, P. & KRELL, R.D. (1981). The effects of nucleotides on the response of the isolated guinea-pig urinary bladder to nonadrenergic, noncholinergic nerve stimulation. *Can. J. Physiol. Pharmac.*, **59**, 1199–1201.
- LUKACSKO, P. & KRELL, R.D. (1982). Response of the guinea-pig urinary bladder to purine and pyrimidine nucleotides. *Eur. J. Pharmac.*, **80**, 401–406.
- MAGUIRE, M.H. & SATCHELL, D.G. (1979). The contribution of adenosine to the inhibitory actions of adenine nucleotides on the guinea-pig taenia coli: Studies with phosphate-modified adenine nucleotide analogs and dipyradamole. *J. Pharmac. exp. Ther.*, **211**, 626–631.
- MAGUIRE, M.H. & SATCHELL, D.G. (1981). Purinergic receptors in visceral smooth muscle. In *Purinergic Receptors. Receptors and Recognition, Series B*, Vol. 12, ed. Burnstock, G. pp. 49–92. London: Chapman & Hall.

(Received September 20, 1983.

Revised November 16, 1983.)